Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.19
$7.05
$3.54
$8.25
$167.53M0.891,861 shs103,470 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.60
-2.9%
$12.75
$6.43
$27.38
$158.63M0.43159,223 shs91,173 shs
MariMed Inc. stock logo
MRMD
MariMed
$0.11
+17.3%
$0.08
$0.07
$0.29
$42.91M2.9408,809 shs503,507 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.41
+0.3%
$3.41
$2.23
$4.13
$169.24M1.29413,564 shs420,249 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Journey Medical Corporation stock logo
DERM
Journey Medical
0.00%+0.56%+10.45%+13.59%+31.68%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+7.99%+3.51%+4.77%+96.22%
MariMed Inc. stock logo
MRMD
MariMed
0.00%-9.90%+33.86%-1.37%-44.88%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.00%+0.29%+6.58%+18.88%-7.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Journey Medical Corporation stock logo
DERM
Journey Medical
2.2729 of 5 stars
3.51.00.00.02.81.70.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3321 of 5 stars
3.50.01.72.73.82.51.3
MariMed Inc. stock logo
MRMD
MariMed
1.0959 of 5 stars
0.05.00.00.01.70.80.6
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
4.246 of 5 stars
3.52.00.00.02.74.23.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Journey Medical Corporation stock logo
DERM
Journey Medical
3.00
Buy$9.5032.13% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50142.06% Upside
MariMed Inc. stock logo
MRMD
MariMed
4.00
Strong BuyN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00105.28% Upside

Current Analyst Ratings Breakdown

Latest MRMD, DERM, LFVN, and PBYI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Journey Medical Corporation stock logo
DERM
Journey Medical
$56.13M2.98N/AN/A$0.91 per share7.90
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.86 per share14.70$2.05 per share6.15
MariMed Inc. stock logo
MRMD
MariMed
$157.96M0.27$0.03 per share4.34$0.16 per share0.69
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.50M0.73$0.85 per share3.99$1.88 per share1.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Journey Medical Corporation stock logo
DERM
Journey Medical
-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.26N/A4.12%34.67%15.24%8/27/2025 (Estimated)
MariMed Inc. stock logo
MRMD
MariMed
-$12.16M-$0.03N/AN/A-10.33%-10.21%-3.12%8/6/2025 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$30.28M$0.774.438.97N/A16.37%49.35%18.25%7/30/2025 (Estimated)

Latest MRMD, DERM, LFVN, and PBYI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.06N/AN/AN/A$14.93 millionN/A
8/7/2025Q2 2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.11N/AN/AN/A$52.00 millionN/A
8/6/2025Q2 2025
MariMed Inc. stock logo
MRMD
MariMed
-$0.01N/AN/AN/A$40.80 millionN/A
5/14/2025Q1 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million
5/7/2025Q1 2025
MariMed Inc. stock logo
MRMD
MariMed
-$0.01-$0.01N/A-$0.01$38.33 million$37.96 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.43%N/A26.09%3 Years
MariMed Inc. stock logo
MRMD
MariMed
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A

Latest MRMD, DERM, LFVN, and PBYI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Journey Medical Corporation stock logo
DERM
Journey Medical
1.07
1.34
1.03
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
MariMed Inc. stock logo
MRMD
MariMed
1.21
1.05
0.37
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.11
1.53
1.43

Institutional Ownership

CompanyInstitutional Ownership
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
MariMed Inc. stock logo
MRMD
MariMed
0.18%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%

Insider Ownership

CompanyInsider Ownership
Journey Medical Corporation stock logo
DERM
Journey Medical
15.03%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
MariMed Inc. stock logo
MRMD
MariMed
18.99%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Journey Medical Corporation stock logo
DERM
Journey Medical
9023.30 million19.80 millionN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
MariMed Inc. stock logo
MRMD
MariMed
260390.43 million316.29 millionNot Optionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million38.07 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.19 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$7.18 -0.01 (-0.14%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.60 -0.37 (-2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$12.60 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

MariMed stock logo

MariMed OTCMKTS:MRMD

$0.11 +0.02 (+17.29%)
As of 03:58 PM Eastern

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.41 +0.01 (+0.29%)
Closing price 04:00 PM Eastern
Extended Trading
$3.40 -0.01 (-0.15%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.